These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16506366)

  • 1. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.
    Chang CY; Huang SP; Chiu HM; Lee YC; Chen MF; Lin JT
    Hepatogastroenterology; 2006; 53(67):1-4. PubMed ID: 16506366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
    Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
    Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of serum TAC-41 in various digestive cancers].
    Sato S; Yamanaka T; Kimura K
    Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
    J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma.
    Tangkijvanich P; Thong-ngam D; Theamboonlers A; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
    Hepatogastroenterology; 2004; 51(55):15-9. PubMed ID: 15011822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
    Santander C; Jiménez I; Martín E; Melón A; Pajares JM
    Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
    Kim JE; Lee KT; Lee JK; Paik SW; Rhee JC; Choi KW
    J Gastroenterol Hepatol; 2004 Feb; 19(2):182-6. PubMed ID: 14731128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical investigation of carbohydrate antigen CA-50].
    Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant or malignant cystic lesions of the pancreas? Results from a single institution experience with 220 surgically treated patients.
    Goh BK; Tan YM; Thng CH; Cheow PC; Chung YF; Chow PK; Wong WK; Ooi LL
    J Am Coll Surg; 2008 Jan; 206(1):17-27. PubMed ID: 18155564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
    Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
    Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?
    Kim BJ; Lee KT; Moon TG; Kang P; Lee JK; Kim JJ; Rhee JC
    Dig Liver Dis; 2009 May; 41(5):364-9. PubMed ID: 19162573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer.
    Goetz M; Steen PD
    Am J Gastroenterol; 1997 Aug; 92(8):1390-1. PubMed ID: 9260821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis.
    Aybek H; Aybek Z; Sinik Z; Demir S; Sancak B; Tuncay L
    Int J Urol; 2006 Nov; 13(11):1380-4. PubMed ID: 17083387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of elevated levels of serum CA 19-9.
    Pavai S; Yap SF
    Med J Malaysia; 2003 Dec; 58(5):667-72. PubMed ID: 15190651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.